



Sales Analytics Advance Export - Basic Information

Refined Options:
 View By: Product Name
 Time Frame: Historical
 Currency: USD
 Key Therapy Area: Cardiovascular
 Key Indication: Pulmonary Arterial Hypertension

Product Id	Product Name	Generic Name	Company Name	Region	First Approva Expiry Year	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016
						Units	Units	Units	Units	Units	Units	Units	Units	Units	Units	Units
13725	Remodulin	treprostinil	United Therapeutics Corp	N/A		152	201	270	332	404	430	458	491	554	573	602
614	Adempas	riociguat	Bayer AG	N/A									4	118	201	282
13766	Juprivi	selecpag	Acelion Ltd	N/A												252
49510	Tracleer	bosentan	Acelion Ltd	US	2001	279	382	464	541	610	689	622	642	615	489	385
2169	Jpsurmit	macitentan	Acelion Ltd	US	2013									5	145	378
6946	Jalaris	ambisentan	Gilead Sciences Inc	US	2007			113	184	240	293	410	520	595	700	819
13725	Tyvaso	treprostinil	United Therapeutics Corp	US	2002					20	152	240	326	439	470	405
309895	Adcirca	tadalafil	United Therapeutics Corp	US	2009											
309895	Adcirca	tadalafil	United Therapeutics Corp	US	2009											
309895	Adcirca	tadalafil	United Therapeutics Corp	US	2009											
9375	Valerit	epoprostenol sodiur	Acelion Ltd	US	2008		130	217	293		36	71	123	177	221	279
62375	Valerit	epoprostenol sodiur	Acelion Ltd	US	2008											159
309895	Adcirca	tadalafil	Eli Lilly and Company	US	2009						2	14	20	32	41	41
3551	Ventavis	iloprost	Eli Lilly and Company	US	2004											20
56893	Folan	epoprostenol sodiur	GlaxoSmithKline Plc	US	1995			88	127	114	120	117	119	123	109	76

ote :

All Units in USD millions
 (F) In Year header notifies forecast data
 Sales are not indication-specific where drugs are approved or in development for multiple indications. Please refer to GlobalData's Disease Analysis reports for indication-specific sales forecasts.
 Sales Regions provided are sourced from company reported financials. Sales Region is shown as N/A where Global sales are not broken out into geographic region.
 Key Therapeutic Area is a unique field in Sales Analytics placing products into a single therapeutic area based on corporate positioning and/or mechanism of action.
 Enhanced views such as Key Target, Key Route of Administration and Key ATC Classification have been specifically added to Sales Analytics to support benchmarking of product-specific attributes
 'Other Pharma and Licensing Revenue' segments forecast data is calculated based on 'Weighted Average Method' so these segments may not have 'AC' data
 Values displayed in blue in the 2016 column represent forecast data
 Values displayed in blue in the CAGR and Difference columns represent calculations based on 2015 actual sales

Extracted Date: 05-Apr-2017

Disclaimer:

All Rights Reserved.
 This information has been extracted from Pharma Intelligence Center by a registered user.
 No part of this publication may be reproduced, stored in a retrieval system or transmitted in any form by any means, electronic, mechanical, photocopying, recording or otherwise, without the prior permission of the publisher, GlobalData.
 GlobalData makes no warranty, representation or guarantee, either express or implied, that the figures or information contained in this publication are accurate, complete or up-to-date. GlobalData shall not be held liable for any loss or damage, including consequential, special or exemplary damages, arising from the use of the information provided in this publication. As such GlobalData can accept no liability whatever for actions taken based on any information that may subsequently prove to be incorrect.



Sales Analytics Advance Export - Basic Information

Refined Options:
 View By: Product Name
 Time Frame: Historical
 Currency: USD
 Key Therapy Area: Cardiovascular
 Key Indication: Pulmonary Arterial Hypertension

Product Id	Product Name	Generic Name	Segment	Company Name	Region	2009	2010	2011	2012	2013	2014	2015	2016
49510	Tracleer	bosentan	Rx	Actelion Ltd	US	541	610	669	622	642	615	489	385
2169	Opsumit	macitentan	Rx	Actelion Ltd	US	-	-	-	-	5	145	373	545
6846	Letairis	ambrisentan	Rx	Gilead Sciences Inc	US	184	240	293	410	520	595	700	819
13725	Remodulin	treprostinil	Rx	United Therapeutics (N/A	332	404	430	458	491	554	573	602
6765	Cozaar/Hyzaar	losartan potassium	Rx	Merck & Co Inc	US	1,321	400	107	28	35	28	30	16
13725	Tyvaso	treprostinil	Rx	United Therapeutics (US	20	152	240	326	439	463	470	405
309895	Adcirca	tadalafil	Rx	United Therapeutics (US	6	36	71	123	177	221	279	372
345688	Revatio	sildenafil citrate	Rx	Pfizer Inc	US	293	293	312	312	67	51	65	98
614	Adempas	riociguat	Rx	Bayer AG	N/A	-	-	-	-	4	118	201	282
13766	Upravi	selexipag	Rx	Actelion Ltd	N/A	-	-	-	-	-	-	-	255
9870	Orenitram	treprostinil diolamine	Rx	United Therapeutics (US	-	-	-	-	-	41	113	157
62375	Veletri	epoprostenol sodium	Rx	Actelion Ltd	US	-	2	14	20	32	37	41	41
309895	Adcirca	tadalafil	Rx	Eli Lilly and Company	US	-	-	19	20	20	20	21	20
3551	Ventavis	iloprost	Rx	Actelion Ltd	US	127	114	120	117	119	123	109	76
56693	Fiolan	epoprostenol sodium	Rx	GaxoSmithKline Plc	US	-	-	71	52	39	-	-	-

Note :

All Units in USD millions
 (F) in Year header notifies forecast data
 Sales are not indication-specific where drugs are approved or in development for multiple indications. Please refer to GlobalData's Disease Analysis reports for indication-specific sales forecasts.
 Sales Regions provided are sourced from company reported financials. Sales Region is shown as 'N/A' where Global sales are not broken out into geographic region.
 Rx = prescription pharmaceuticals; Other Pharma = Pharmaceutical sales not broken out into individual Segments; Other Revenue = Other revenue segments that do not conform to GlobalData's defined segment list.
 Key Therapy Area is a unique field in Sales Analytics placing products into a single therapeutic area based on corporate positioning and/or mechanism of action.
 Enhanced views such as Key Target, Key Route of Administration and Key ATC Classification have been specifically added to Sales Analytics to support benchmarking of product-specific attributes.
 'Other Pharma' and 'Licensing Revenue' segments forecast data is calculated based on 'Weighted Average Method' so these segments may not have 'AC' data
 Values displayed in blue in the 2016 column represent forecast data
 Values displayed in blue in the CAGR and Difference columns represent calculations based on 2015 actual sales

Extracted Date: 05-Apr-2017

Disclaimer:

All Rights Reserved.
 This information has been extracted from Pharma Intelligence Center by a registered user.
 No part of this publication may be reproduced, stored in a retrieval system or transmitted in any form by any means, electronic, mechanical, photocopying, recording or otherwise, without the prior permission of the publisher, GlobalData.
 The facts of this report are believed to be correct at the time of publication but cannot be guaranteed. Please note that the findings, conclusions and recommendations that GlobalData delivers will be based on information gathered in good faith from both primary and secondary sources, whose accuracy we are not always in a position to guarantee. As such GlobalData can accept no liability whatever for actions taken based on any information that may subsequently prove to be incorrect.